公开(公告)号：US20240085427A1

公开(公告)日：2024-03-14

申请号：US18259640

申请日：2022-01-04

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Nathan G. DOLLOFF ,  Reeder M. ROBINSON

IPC: G01N33/574 ,  C07K16/28

CPC classification number: G01N33/57488 ,  C07K16/283 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/94 ,  G01N2333/99

Abstract: The present disclosure is directed to antibodies binding to AGR2 and cancer cells that express or overexpress AGR2, and methods for use thereof.

公开(公告)号：US20200165182A1

公开(公告)日：2020-05-28

申请号：US16633464

申请日：2018-08-29

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Nathan G. DOLLOFF ,  Reeder M. ROBINSON ,  Allen B. REITZ ,  Haiyan BIAN

IPC: C07C39/38 ,  C07D263/52 ,  C07C69/708 ,  A61P35/00 ,  C07C233/02 ,  C07D319/14 ,  C07C61/29 ,  C07C233/58 ,  C07D317/52 ,  C07C43/225

Abstract: The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.